The Pharma Data

OCTOBER 15, 2020

a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Science Disease 40

The Pharma Data

JULY 22, 2021

(NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. Chief Executive Officer at Arvinas.

Targeted Protein Degradation 52

Targeted Protein Degradation Therapies Clinical Trials Treatment 52

Drug Hunter

AUGUST 21, 2023

Obtaining adequate drug exposure in the brain is key to treating CNS diseases effectively. Prodrugs Remain in “Proof-of-Concept” Stages Prodrug strategies for CNS deliver have also been applied with varying success , with the most famous example being L-Dopa for Parkinson’s disease. Figure 18.

Drugs 206

Drugs Disease Targeted Protein Degradation Screening Hits 206

The Pharma Data

SEPTEMBER 15, 2020

The companies will receive priority admission or renewal for one year of lab bench space with access to core facilities at the MBC BioLabs life sciences incubator, including access to Amgen ‘s scientific experts and business leaders to help advance their scientific programs.

Targeted Protein Degradation 52

Targeted Protein Degradation Molecular Biology Small Molecule Science 52

Elrig

MARCH 22, 2023

Therapeutic oligos, such as ASOs, siRNAs, and other mRNA-targeted therapeutics, have emerged as an exciting modality with the potential to address a variety of previously untreatable conditions. Freely accessible, high-quality science is critical for innovation,” added Dr Katja Herzog, Senior Project and Grant Manager, EU-OPENSCREEN.

Targeted Protein Degradation 40

Targeted Protein Degradation Science Disease Laboratories 40

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. This targeted delivery allows enhanced therapeutic efficacy while reducing the harmful side effects commonly associated with traditional chemotherapy.

Small Molecule 127

Small Molecule Drugs Immune Response Targeted Protein Degradation 127

LifeSciVC

OCTOBER 28, 2024

In part a reasonable and justified reaction to the over-hyped “big science project” platforms funded during the pandemic bubble, this sentiment needs to considered in the context of how the innovation pendulum swings back and forth over cycles. Today’s common refrain around “assets-in, platforms-out” is pervasive.

Licensing 91

Licensing Licensing Marketing Targeted Protein Degradation 91

LifeSciVC

FEBRUARY 5, 2025

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC In the perpetual and never-ending race by the healthcare sector to unearth new approaches and therapeutics to address disease, one area in which we are seeing novel innovation is in the targeting of transcription factors.

Small Molecule 67

Small Molecule Targeted Protein Degradation Regulations Disease 67